Q32 Bio Stock Plummets After Bempikibart Fails Eczema Trial but Shows Promise in Alopecia

Following the disappointing results of the phase 2 eczema trial for Q32 Bio's experimental drug bempikibart, the company's stock took a significant hit, plummeting by approximately 65%[1][2]. The trial failed to meet its primary efficacy endpoint, with the drug showing no significant improvement over placebo in reducing the severity of eczema symptoms[1]. Despite the eczema setback, bempikibart demonstrated some promise in treating alopecia areata, although the results were considered confounded by protocol issues during the trial[2]. As a consequence of the "messy" trial outcomes, analysts drastically lowered their expectations for the company's financial performance, further contributing to the stock's rapid decline[2].